CEBM and BMJ logo

Manifesto References

References

  1. Bastian, H., Hilda, B., Paul, G. & Iain, C. Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up? PLoS Med. 7, e1000326 (2010).
  2. Goldacre, B. Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients. (Macmillan, 2014).
  3. Altman, D. G. The scandal of poor medical research. BMJ 308, 283–284 (1994).
  4. Chalmers, I. & Glasziou, P. Avoidable waste in the production and reporting of research evidence. Lancet 374, 86–89 (2009).
  5. Light, D. W., Lexchin, J. & Darrow, J. J. Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. J. Law Med. Ethics 41, 590–600 (2013).
  6. Bekelman, J. E., Li, Y. & Gross, C. P. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289, 454–465 (2003).
  7. Greenhalgh, T., Snow, R., Ryan, S., Rees, S. & Salisbury, H. Six ‘biases’ against patients and carers in evidence-based medicine. BMC Med. 13, 200 (2015).
  8. Yudkin, J. S., Lipska, K. J. & Montori, V. M. The idolatry of the surrogate. BMJ 343, d7995 (2011).
  9. Gøtzsche, P. C. et al. Ghost authorship in industry-initiated randomised trials. PLoS Med. 4, e19 (2007).
  10. Song, F. et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol. Assess. 14, iii, ix–xi, 1–193 (2010).
  11. McGauran, N. et al. Reporting bias in medical research – a narrative review. Trials 11, (2010).
  12. Saini, P. et al. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ 349, g6501 (2014).
  13. Dodd, S., Susanna, D., Ian, W. & Paula, W. Departure from treatment protocol in published randomised controlled trials: a review. Trials 12, A129 (2011).
  14. Montori, V. M. et al. Randomized trials stopped early for benefit: a systematic review. JAMA 294, 2203–2209 (2005).
  15. Ahmed, L. & Laura, A. Bad Pharma: How drug companies mislead doctors and harm patients. Australian Prescriber 36, 55–55 (2013).
  16. Ioannidis, J. P. A. Why most published research findings are false. PLoS Med. 2, e124 (2005).
  17. Kessel, M. & Mark, K. Restoring the pharmaceutical industry’s reputation. Nat. Biotechnol. 32, 983–990 (2014).
  18. Masoudi, F. A. et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am. Heart J. 146, 250–257 (2003).
  19. Lenzer, J. Why we can’t trust clinical guidelines. BMJ 346, f3830–f3830 (2013).
  20. Onakpoya, I. J., Heneghan, C. J. & Aronson, J. K. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 14, 10 (2016).
  21. Dusetzina, S. B. Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014. JAMA Oncol 2, 960–961 (2016).
  22. Moynihan, R., Heneghan, C. & Godlee, F. Too much medicine: from evidence to action. BMJ 347, f7141 (2013).
  23. Collier, R. Rapidly rising clinical trial costs worry researchers. Can. Med. Assoc. J. 180, 277–278 (2009).
  24. Shay, L. A. & Lafata, J. E. Where Is the Evidence? A Systematic Review of Shared Decision Making and Patient Outcomes. Med. Decis. Making 35, 114–131 (2014).
  25. Greenhalgh, T., Howick, J., Maskrey, N. & Evidence Based Medicine Renaissance Group. Evidence based medicine: a movement in crisis? BMJ 348, g3725 (2014).
  26. Goldacre B. Heneghan C. How medicine is broken, and how we can fix itBMJ 2015; 350  (Published 23 June 2015) Cite this as: BMJ 2015;350:h3397. (Accessed: 26th August 2016)

 

2020 Registration
OPEN

Call for Oral & Poster Abstracts
OPEN